News Release

New model recreates early spread of Parkinson’s disease in the brain

GRAND RAPIDS, Mich. (Aug. 8, 2016)—They’re two of the biggest mysteries in Parkinson’s disease research—where does the disease start? And how can it be stopped early in the process?

Now, a new laboratory model of Parkinson’s is giving scientists an inside look at what happens in the brain years before motor symptoms appear. Specifically, it demonstrates how abnormal alpha-synuclein proteins, which are strongly associated with Parkinson’s, gradually spread from an area of the brain implicated in the early stages of the disease to other regions of the brain ultimately damaged by the disease. The findings were published today in the Journal of Experimental Medicine.

Parkinson’s is primarily a disease of aging, with most cases diagnosed after age 60. By the time symptoms appear, more than half of the brain cells that produce dopamine, a chemical messenger needed for voluntary movement, have died. What triggers this process is unknown, although evidence points to a combination of genetic, epigenetic and environmental factors. Strong evidence also suggests that clumps of abnormal alpha-synuclein play a role in the disease process. In recent years, scientists have found links to the early stages of Parkinson’s in other areas of the body, namely the gut and the nose.

“Better models that mimic the early stages of the disease will allow us to more precisely study Parkinson’s and, by extension, find new ways to potentially stop it before it progresses,” said Van Andel Research Institute researcher Nolwen L. Rey, Ph.D., the study’s first author. “We know that specific signs of Parkinson’s, including a loss of sense of smell, appear years before the onset of motor symptoms. Our new model replicates the phase that occurs long before diagnosis and, importantly, gives us a powerful tool to test novel interventions that might prevent the onset of Parkinson’s as we know it.”

The study demonstrates that alpha-synuclein travels along nerve cells in the olfactory bulb—the part of the brain that controls sense of smell—prior to the onset of motor symptoms and that this area may be particularly susceptible to the spread of alpha-synuclein, ultimately causing deficits in the sense of smell. Clumps of alpha-synuclein eventually reach several additional brain regions, including the brainstem area that houses dopamine cells.

“Perhaps most remarkably, we have created a model of prodromal Parkinson’s disease, the condition that precedes the diagnosis of the disorder in humans by five to 10 years, that successfully mimics the pattern of alpha-synuclein’s pathology in the brain,” said Patrik Brundin, M.D., Ph.D., senior author of the study and director of Van Andel Research Institute’s Center for Neurodegenerative Science. “Not only might this teach us something about how the disease develops and the importance of the olfactory system, but the model will also prove invaluable when testing novel therapeutics designed to slow down or stop the progression of disease.”

###

This work was supported by Van Andel Research Institute, the Peter C. and Emajean Cook Foundation, the European Research Council and University of Pennsylvania Morris K. Udall Parkinson’s Disease Research Center of Excellence. Other study authors include Jennifer A. Steiner (Van Andel Research Institute), Nazia Maroof (Roche Innovation Center), Kelvin C. Luk (University of Pennsylvania), Zachary Madaj (Van Andel Research Institute), John Q. Trojanowski (University of Pennsylvania), and Virginia M-Y Lee (University of Pennsylvania).

Parkinson’s disease: Between seven and 10 million people worldwide have Parkinson’s disease. In addition to its hallmark motor symptoms, including loss of voluntary movement, rigidity and tremor, Parkinson’s also has a host of non-motor symptoms such as cognitive impairment and gastrointestinal issues. Although there are therapies to mitigate symptoms, there currently are no treatments that actually prevent the disease or that change its course.

Alpha-synuclein: Alpha-synuclein is a protein with a yet undefined function in normal health. In Parkinson’s, abnormal versions of this protein clumps together to form Lewy bodies, a hallmark sign of the disease in the brain.

ABOUT VAI

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is committed to improving the health and changing the lives of current and future generations, through biomedical research and science education.